Cartilage tissue engineering using ADAMTS-4/5 deficient mesenchymal stem cells  by Wang, D. et al.
Abstracts / Osteoarthritis and Cartilage 23 (2015) A82eA416A142size) were determined by SEM. For cell culture studies, 5mm explants
punched from bovine articular cartilage were wounded with a scalpel
and equilibrated in culture for 24h. Explants were subsequently incu-
bated with 0 or 10ng/mL of IL-1b and/or microcapsules with or without
encapsulated CNP for 96h. At the end of the culture period, samples
were analysed for NO release and GAG loss (%). Chondrocyte % viability
was assessed by incubation with calcein-AM and EtBr-1(5mM), and
quantiﬁed by ImageJ analysis. Confocal microscopy was used to detect
interaction of CNP microcapsules by incubating chondrocytes with
antibodies to natriuretic peptide receptor (Npr) 2 and 3.
Results: SEM showed uniform, 2-3 mm spherical microcapsules with
morphological characteristics similar in templates loaded with or
without CNP. The protein was localized around the inner surface of the
microcapsule shell with encapsulation efﬁciencies >82.9%. CNP release
proﬁles were broadly similar following 1-9 days of culture. The pres-
ence of CNP microcapsules did not signiﬁcantly affect cell viability
(>80%), with DNA values that remained stable throughout theculture
conditions. Microcapsules were shown to localise to wounded areas of
the explants, and confocal imaging showed clustering of microcapsules
in chondrocytes to natriuretic peptide receptor (Npr) 2 and 3. Fur-
thermore, treatment of cartilage explants with CNP microcapsules led
to concentration-dependent inhibition of NO release in response to IL-
1band restoration of matrix synthesis.
Conclusions: The present study reproducibly generated uniform
microcapsules with homogeneous morphological characteristic suit-
able for delivery and retention in the articular joint. The microcapsule
delivery system is highly effective for CNP since the peptide could be
stabilised through electrostatic interaction with the polyelectrolyte
layers sufﬁcient to allow diffusion of active CNP after localisation to
areas of damage. Furthermore, treatment of cartilage explants with
bioactive concentrations of CNP led to protective effects with sustained
release of CNP in a manner responsive to the local environment. In
summary, we demonstrate for the ﬁrst time controlled delivery of CNP
to dampen inﬂammatory effects induced by IL-1bin cartilage explants
that has the potential to promote cartilage repair in vivo.
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OBESITY DOES NOT NEGATIVELY INFLUENCE CARTILAGE REPAIR OR
CAUSE OSTEOARTHRITIS IN DBA/1 MICE
W. Wei y, Y.M. Bastiaansen-Jenniskens y, K.P. Bos y, J.A. Verhaar y,
A.-M. Zuurmond y, F. Dell'Accio z, G.J. Van Osch y. y Erasmus Univ. Med.
Ctr., Rotterdam, Netherlands; zQueen Mary Univ., London, United
Kingdom
Purpose: Traumatic cartilage damage, if left untreated, could eventually
increase the risk of developing osteoarthritis (OA). Marrow stimulation
treatments, such as microfracture, are performed to stimulate intrinsic
cartilage repair. The symptomatic improvements of microfracture are
reported to be less in obese patients and these patients are now often
excluded from treatment. Obesity is a major risk factor for OA and leads
to low grade systemic inﬂammation and metabolic changes. There is
however no convincing evidence that intrinsic cartilage repair is neg-
atively inﬂuenced by obesity. To optimize cartilage repair treatments
and to prevent OA development in obese patients, it is therefore
essential to investigate whether and how obesity inﬂuences cartilage
repair. In this study we investigated the effects of obesity on cartilage
repair and OA development in the DBA/1 mouse strain. Our hypothesis
was that obesity negatively inﬂuences intrinsic cartilage repair and
accelerates the speed of OA development after cartilage damage.
Methods: Ten-weeks-old male DBA/1 mice were fed with control diet
or obesity inducing high fat diet (HFD; 60% energy from fat). After two
weeks, a full thickness cartilage defect wasmade in the trochlear groove
of the left knee. Mice were sacriﬁced after 1 (n¼6 mice per diet), 8 (n¼9
mice per diet) and 24 (n¼5 mice per diet) weeks. Cartilage repair was
evaluated on histology using the Pineda scoring method and OA
development was evaluated using the OARSI scoring method.
Results:Mice on a HFD had higher bodyweight whenmaking the defect
(31.0±1.7gr versus 27.2±1.1gr; p<0.001) and the difference became even
larger after 24 weeks (42.0±5.8gr versus 31.7±4.6gr; p<0.001). One
week after defect creation, mice on HFD had a higher percentage of
defect ﬁlling with ﬁbroblast-like cells in the defect. After 8 weeks, mice
on a HFD had more cartilage repair as indicated by a lower Pineda score(p¼0.01). After 24 weeks, no mice had complete cartilage repair and we
were not able to detect a statistically signiﬁcant difference in Pineda
score between mice on HFD and control diet with this group size. All
mice at every time point had an OARSI score of 0, indicating no signs of
osteoarthritis.
Conclusions: Obesity did not negatively affect intrinsic cartilage repair
in DBA/1 mice. Obesity did not cause OA in DBA/1 mice, even in com-
bination with induced traumatic cartilage damage. Future research into
the inﬂammatory and metabolic changes after a high fat diet in this
strain of mice could provide more insights into the link between obesity
related changes, cartilage damage and OA development.
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CARTILAGE TISSUE ENGINEERING USING ADAMTS-4/5 DEFICIENT
MESENCHYMAL STEM CELLS
D. Wang, S. Chen, M. Esterban, M. Tortorella. Guangzhou Inst.s of
biomedicine and Hlth., CAS, Guangzhou, China
Purpose: Aggrecan is one of the two major constituents of articular
cartilage, and during diseases such as osteoarthritis (OA) it is subject to
degradation by proteolytic enzymes. The primary proteases responsible
for aggrecan cleavage are the aggrecanases, identiﬁed as members of
the disintegrin and metalloproteinase with thrombospondin motifs
(ADAMTS) family of proteases. Aggrecanase 1(ADAMTS-4) and aggre-
canase 2 (ADAMTS-5) have been reported as important therapeutic
targets in osteoarthritis. However, there is still debate which of them is
the major aggrecanase responsible for the degradation of aggrecan in
human cartilage. The aim of this study was to generate ADAMTS-4
deﬁcient and ADAMTS-5 deﬁcient chondroprogenitors derived form
human induced pluripotent stem cells (iPSCs) to enable the evaluation
of the respective roles of ADAMTS-4 and ADAMTS-5 in human cartilage
breakdown.
Methods: ADAMTS-4 deﬁcient and ADAMTS-5 deﬁcient human iPS
cells were produced by knockout of these genes in iPS cells using
Transcription Activation-Like Effector nucleases (TALENs). These iPS
cells were differentiated into chondrogenic lineage via generation of
mesenchymal stem cells (MSCs) using a multistep culture method
consisting of embryoid body (EB) formation, cell outgrowth from EBs,
monolayer culture of sprouted cells from EBs, and 3-demensional pellet
culture. Interleukin-1 (IL-1) and tumor necrosis factor (TNF) treatment
were applied after chondrogenic differentiation. The expression of type
II collagen, aggrecan, ADAMTS4, and ADAMTS-5 was measured by
quantitative real-time PCR, Western blotting, and immunoﬂuorescence
staining. The production of collagen and glycosaminoglycan (GAG) was
quantiﬁed by dye binding assays.
Results: ADAMTS-4/5 deﬁcient iPSC-derived MSCs exhibited ﬁbroblast-
like morphology similar to bone marrow MSCs and expressed surface
markers for MSCs. After 4-6 weeks of pellet culture, cells in pellet
exhibited a spherical morphology typical of chondrocytes. The
expression of type II collagen and aggrecan in pellets progressively
increased. Histological analysis revealed that ADAMTS-4/5 deﬁcient
MSC-derived pellets successfully underwent chondrogenic
differentiation.
Conclusions: These results demonstrate a model system of chon-
droprogenitors from genetically modiﬁed human iPSCs. This work also
provides potential iPSC progeny for developing cell-base approaches to
repair joint cartilage damage.
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EXTRACELLULAR MATRIX CHANGES IN RESPONSE TO SPRIFERMIN
STUDIED IN EX VIVO CULTURES OF ARTICULAR CARTILAGE
D. Reker y, A. Gigout z, C. Ladel z, M. Karsdal y, A. Bay-Jensen y. yNordic
BioSci., Herlev, Denmark; zMerck KGaA, Darmstadt, Germany
Purpose: Osteoarthritis (OA) is a degenerative disease with high
prevalence, creating an unmet medical need for drugs to protect and
regenerate cartilage. Sprifermin, a truncated form of ﬁbroblast growth
factor 18 (rhFGF18), is being investigated as a potential disease-mod-
ifying OA drug (DMOAD). Sprifermin has been shown to increase car-
tilage volume in the knees of OA patients. The few studies published
about the mode of action behind its anabolic effects, indicate that full-
